Symbols

EYPT

EyePoint·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EYPT

Eyepoint, Inc.

A pharmaceutical company that focused on ophthalmic treatments

Industry

Pharmaceutical

Established Date

03/19/2008

Listing Date

06/20/2008

Exchange

NASDAQ Stock Exchange

Full-time Employees

165

Fiscal Year Ends

12-31

Website

www.eyepointpharma.com

Security Type

Common stock

Office address

480 Pleasant Street, Watertown, MA 02472

Business

Introduction

EyePoint, Inc., incorporated in Delaware on March 19, 2008, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies to help improve the lives of patients with severe retinal diseases. The Company adopts its proprietary biodegradable Durasert E ™Technology for continuous intraocular drug delivery, thus solving the problem caused by frequent intravitreal injections. Its main product candidate DURAVYU ™It is an investigational therapy for the treatment of vascular endothelial growth factor-mediated retinal diseases.

Earnings Call

Q1/2025

Estimate EPS-0.69

Actual EPS-0.65

Estimate Revenue8.84M

Actual Revenue24.45M

EyePoint Pharmaceuticals: Key Contradictions in Phase 3 Trial Timelines and FDA Interactions

May 07,2025 03:04·
Earnings Decrypt

Q2/2025

Estimate EPS-0.8

Actual EPS-0.85

Estimate Revenue6.16M

Actual Revenue5.30M

Contradictions Unveiled: Regulatory Strategies and Trial Timelines in Latest Biopharma Call

Aug 06,2025 04:21·
Earnings Decrypt

Q3/2025

Estimate EPS-0.77

Actual EPS-0.85

Estimate Revenue3.33M

Actual Revenue966.00K

EyePoint's Q3 2025: Contradictions Emerge on DME Trial Endpoints, Enrollment Timing, and Design

Nov 05,2025 02:51·
Earnings Decrypt

Company Financials

EPS

EYPT has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -0.77, missing expectations. The chart below visualizes how EYPT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EYPT has released its 2025 Q3 earnings report, with revenue of 966.00K, reflecting a YoY change of -90.82%, and net profit of -59.73M, showing a YoY change of -103.44%. The Sankey diagram below clearly presents EYPT's revenue sources and cost distribution.